2 unknown, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Terminated 1 |
Follow ImmunoPulse: new trials by email Literature Review of ImmunoPulse trials Research Report on ImmunoPulse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat ImmunoPulse, Epacadostat, Pembrolizumab - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | Chase Heaton, MD | 14 | 2019-05-02 | 2023-05-09 |
| Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC tavokinogene telseplasmid, Pembrolizumab, Immunopulse - Triple Negative Breast Cancer | Phase 2 | Unknown | OncoSec Medical Incorporated | 65 | 2018-10-11 | 2023-06-01 |
| Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment tavokinogene telseplasmid, Pembrolizumab, ImmunoPulse - Stage III/IV Melanoma | Phase 2 | Unknown | OncoSec Medical Incorporated | 143 | 2017-10-03 | 2023-03-27 |
Melanoma (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
OncoSec Medical Incorporated (2) · Chase Heaton, MD (1)
United States (3) · Australia (2) · Canada (1) · Italy (1) · Switzerland (1)
Bridget O'Keeffe (1) · Bridget O'Keeffe, PhD (1) · Chase Heaton, MD (1)